|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 56.18 USD | +3.91% |
|
-12.54% | +83.35% |
| 07-22 | What Bundibugyo Ebola vaccines and treatments are under development | RE |
| 07-22 | Biotech experts want FDA drug reviews based on science, not politics | RE |
| Market Cap | 21.45B 18.84B 17.52B 16.08B 30.21B 2,066B 30.68B 208B 81.3B 1,016B 80.54B 78.8B 3,512B | P/E 2026 * |
-6.24x | P/E 2027 * | -11.4x |
|---|---|---|---|---|---|
| Enterprise Value | 18.05B 15.85B 14.74B 13.53B 25.42B 1,738B 25.81B 175B 68.39B 854B 67.75B 66.29B 2,954B | EV / Sales 2026 * |
8.63x | EV / Sales 2027 * | 7.62x |
| Free-Float |
92.69% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Moderna, Inc.
| 1 day | +4.41% | ||
| 1 week | -12.54% | ||
| Current month | -22.79% | ||
| 1 month | -19.62% | ||
| 3 months | +6.58% | ||
| 6 months | +12.67% | ||
| Current year | +83.35% |
| 1 week | 53.85 |  | 60.83 |
| 1 month | 53.85 | | 85.6 |
| Current year | 29.81 | | 85.6 |
| 1 year | 22.28 | | 85.6 |
| 3 years | 22.28 | | 170.47 |
| 5 years | 22.28 | | 497.49 |
| 10 years | 11.54 | | 497.49 |
| Manager | Title | Age | Since |
|---|---|---|---|
Stéphane Bancel
CEO | Chief Executive Officer | 54 | 28/02/2011 |
James Mock
DFI | Director of Finance/CFO | 49 | 05/09/2022 |
Stephen Hoge
PSD | President | 50 | 31/10/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Noubar Afeyan
CHM | Chairman | 63 | 31/01/2012 |
Stéphane Bancel
BRD | Director/Board Member | 54 | 28/02/2011 |
Francois Nader
BRD | Director/Board Member | 69 | 10/12/2019 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 15/07/26 | Fiscal year | Chairperson | 160,008 | 0.0403% | ||
| 08/07/26 | Free | Director | 14,766 | 0.0037% | ||
| 05/07/26 | Free | Executive/Senior Manager | 57,022 | 0.0144% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +3.91% | -12.54% | +58.33% | -55.18% | 21.45B | |
| +1.89% | -3.06% | +16.50% | -10.25% | 66.74B | |
| 0.00% | +3.32% | +37.49% | +204.11% | 53.32B | |
| +10.08% | +51.80% | +51.80% | +51.80% | 48.12B | |
| +1.90% | -5.07% | -56.99% | -56.52% | 38.25B | |
| +0.06% | -1.84% | +53.73% | -23.77% | 29.85B | |
| +1.45% | +0.36% | +67.62% | +87.37% | 23.51B | |
| +1.80% | +3.24% | +81.47% | +159.24% | 16.47B | |
| +1.18% | -0.30% | +63.80% | +125.61% | 16.38B | |
| +1.46% | +4.78% | +139.02% | +216.27% | 12.4B | |
| Average | +2.42% | -0.17% | +51.28% | +69.87% | 32.65B | |
| Weighted average by Cap. | +2.71% | +0.19% | +36.66% | +55.29% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 2.09B 1.84B 1.71B 1.57B 2.95B 201B 2.99B 20.29B 7.93B 99.03B 7.85B 7.68B 342B | 2.55B 2.24B 2.08B 1.91B 3.59B 245B 3.64B 24.71B 9.65B 121B 9.56B 9.36B 417B |
| Net income | -3.41B -3B -2.79B -2.56B -4.81B -329B -4.88B -33.12B -12.94B -162B -12.82B -12.54B -559B | -1.85B -1.63B -1.51B -1.39B -2.61B -178B -2.65B -17.97B -7.02B -87.71B -6.95B -6.8B -303B |
| Net Debt | -3.41B -2.99B -2.78B -2.55B -4.8B -328B -4.87B -33.04B -12.91B -161B -12.79B -12.51B -558B | -2.05B -1.8B -1.68B -1.54B -2.89B -198B -2.94B -19.91B -7.78B -97.2B -7.71B -7.54B -336B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24/07/26 | US$54.07 | -5.17% | 4,427,772 |
| 23/07/26 | US$57.02 | -1.81% | 4,695,588 |
| 22/07/26 | US$58.07 | -2.67% | 3,780,416 |
| 21/07/26 | US$59.66 | +0.29% | 4,357,386 |
| 20/07/26 | US$59.49 | -3.77% | 4,967,920 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- MRNA Stock
Select your edition
All financial news and data tailored to specific country editions
